Rhenman & Partners Asset Management’s Aimmune Therapeutics AIMT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-285,000	Closed	-$4.76M	–	94
2020 Q2	$4.76M	Buy	285,000 +120,000	+73%	+$2.04M	0.51%	64
2020 Q1	$2.38M	Buy	165,000 +15,000	+10%	+$383K	0.33%	73
2019 Q4	$5.02M	Buy	150,000 +799	+0.5%	+$22.3K	0.55%	63
2019 Q3	$3.12M	Hold	149,201	–	–	0.39%	67
2019 Q2	$3.11M	Hold	149,201	–	–	0.34%	65
2019 Q1	$3.33M	Buy	+149,201	New	+$3.51M	0.39%	66

Other funds holding AIMT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Rhenman & Partners Asset Management's AIMT Position: Q3 2020 in Review

Rhenman & Partners Asset Management sold out of Aimmune Therapeutics (AIMT) in Q3 2020, closing a stake of 285,000 shares — an estimated $4.76M sold.

Rhenman & Partners Asset Management first reported a position in AIMT in Q1 2019 and held it in 6 quarters. The position peaked at $5.02M in Q4 2019. 188 funds tracked by Wall St. Rank hold AIMT as of Q3 2020.

Rhenman & Partners Asset Management reported no remaining Aimmune Therapeutics position as of Q3 2020 after selling out during the quarter.
Rhenman & Partners Asset Management sold 285,000 Aimmune Therapeutics shares in Q3 2020, an estimated $4.76M.
Rhenman & Partners Asset Management first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 6 quarters.
Rhenman & Partners Asset Management's Aimmune Therapeutics position peaked at $5.02M in Q4 2019.
188 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q3 2020.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2020, filed 13 Oct 2020.